Sunday, November 22, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain WeeklyRobinhood Chain Daily
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyTerms of serviceCorrectionsAccuracy recordRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 55

Compass Pathways bets on fast FDA review for psilocybin depression drug

Compass Pathways has wrapped its FDA application for COMP360, a synthetic psilocybin treatment for treatment-resistant depression, after two Phase 3 trials in nearly 900 patients hit positive results. CEO Kabir Nath says a National Priority Voucher could speed review, with a launch targeted for the first half of next year.

By the Paparazzi desk November 22, 2026 · 6:11 AM · finance.yahoo.com · 2 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: finance.yahoo.com.
  • The source published it on Nov 22, 2026 at 6:11 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Compass Pathways has finished its FDA application for COMP360, its experimental synthetic psilocybin treatment for treatment-resistant depression. The filing covers two Phase 3 trials that enrolled close to 900 patients and delivered statistically significant positive results, backed by an earlier Phase 2b study. CEO Kabir Nath, speaking at a Jefferies event, said the company expects to launch in the first half of next year, with readiness by the end of this year if regulators sign off.

A Commissioner's National Priority Voucher is now in hand, and Nath said it could set up a rapid FDA review. Compass already had a rolling submission and review agreement before the voucher arrived, he added. Jefferies analyst Andrew Tsai pegged Nov. 9 as the date the application was completed.

Sponsored

Nath said the FDA had been reviewing submitted modules all along, and that Compass has no reason to think the agency is walking back its stated aim of finishing the review within one to two months of the completed submission. He also expects the application to be accepted with a PDUFA date, though he doesn't know when that lands. Whenever it's assigned, he said, it could reflect a standard six-month priority review that the FDA might beat.

For the commercial push, Compass plans to ride existing SPRAVATO treatment centers, with 9,000 or more sites expected by launch. Nath estimated COMP360 would need two to four doses a year per patient. He said the company expects to price it at a premium to SPRAVATO, while warning that insurers may drag their feet on coverage at first. Everything hinges on approval and rescheduling.

TopicsCompass Pathways · COMP360 · Kabir Nath · FDA · Jefferies · Andrew Tsai · SPRAVATO · NASDAQ: CMPS

Share

Source: finance.yahoo.com

Written by AI from verified reporting.

More stories

  • Health & science 14:46 UTC · 1 hour ago · ruibao.news · 2 views
    FDA Rejects Akeso's Ivonescimab, Citing China-Heavy Trial Data
  • Health & science 14:20 UTC · 2 hours ago · theguardian.com · Caught by @pipio · 2 views
    Trusted Messengers Hold the Key to Stopping the Amish Measles Outbreak
  • Health & science 05:44 UTC · 10 hours ago · simplywall.st 2 sources· 2 views
    Alnylam Notches Seventh FDA Approval as Livsayis Clears Myasthenia Gravis
  • Health & science 05:17 UTC · 11 hours ago · sciencealert.com · Caught by @ajayy30 · 1 view
    Kids With More Screen Time Scored Better on Teen Brain Tests, 8-Year Study Finds
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.